Interesting...
Our People at Kenna
Barbara Handelin, Ph.D., President, CEO & Co-Founder, is an internationally recognized business executive and scientist with 13 years of executive management experience in R&D and product commercialization in the biotech, bio-pharmaceutical, and genomics industries. Dr. Handelin’s previous business experience includes company start-up and financing (Genovo, a gene therapy company), executive consulting, and building a worldwide business division (DNA Diagnostics Lab at Integrated Genetics, now Genzyme Genetics).
L. Tandy Herren, Ph.D., Chief Technology Officer & Co-Founder, is an expert in interface technologies and artificial intelligence with over ten years of applied biological modeling experience in the research (Southwest Research Institute) and the biotechnology (Interleukin Genetics) industries. Dr. Herren is co-author of the issued U.S. patent that supports Kenna’s interface technology.
Wonder if we're going to be receiving input from their current advisors:
Key Advisors and Directors
David E. Housman, Ph.D. - Co-Founder & Advisor. Dr. Housman is the Ludwig Professor of Biology at the Massachusetts Institute of Technology and a National Academy of Sciences and the Institute of Medicine fellow. He serves on Medical and Scientific Advisory boards of five foundations, including the Merck Genome Institute, the Cure Huntington's Disease Institute and the National Neurofibromatosis Foundation. Dr. Housman was the scientific co-founder of one of the earliest biotechnology companies, Integrated Genetics, (1981) followed by Variagenics, a privately held pharmacogenomics company.
Richard Sherman, Esq.: Mr. Sherman is a Managing Officer of QED Technologies, Inc., a strategic consulting firm for life science-based companies, a Principal of CIP Capital Management, Inc., and as Counsel to the law firm of Goodsill, Anderson, Quinn & Stifel, in Honolulu, Hawaii. Prior to forming QED, Mr. Sherman was Deputy General Counsel at SmithKline Beecham Corporation (now GlaxoSmithKline). Mr. Sherman has served as Director of IBAH, Inc., Sparta Pharmaceuticals, Inc., and Cytomed, Inc. Currently, he is a Board member of Pennsylvania Biotechnology Association, member of the Board of Trustees of the Crossroads School, and Director of Biophage, Inc., of Montreal, Canada, Aquasearch, Inc. of Kona, Hawaii, and Hawaii Biotechnology Group, Inc. of Honolulu, Hawaii.
Romeo Bachand, M.D., Ph.D.- Director: Dr. Bachand is currently Senior Vice President and Chief Scientific Officer at Auxilium, A2, Inc., Prior to joining Auxilium, Dr. Bachand was at Abbott International over a 14 year period including most recent post as Vice President, Global Clinical Development, Vice President, Scientific & Medical Affairs and Quality Assurance and Venture Head for the Macrolides division. Dr. Bachand serves on the Scientific Advisory Committee of Genomics Collaborative, Inc. (Cambridge, Mass), the New York Medical College Graduate School of Health Sciences & Sir Patrick Dun’s Institute (Dublin, Ireland) Advisory Board (New York, NY) and the Pharmaceutical Foundation Advisory Council at University of Texas, Austin as well as on the Board of Trustees of the American Heart Association.
James McCormick, M.D.- Director: Dr. McCormick is Director of Laboratory Medicine, Swedish Covenant Hospital and Chairman of the Board, LifeCenter on the Green, Inc. (affiliate Swedish Covenant). Dr. McCormick holds 42 patents for laboratory medicine products, which he has licensed and directly helped to commercialize over the last 45 years. Dr. McCormick’s deep experience in the executive management of high quality health care is reflected by his status in several prestigious national organizations. He recently finished serving on the board of the National Museum of Health and Medicine, is a Distinguished Fellow of the American College of Physician Executives and a Fellow of the American College of Healthcare Executives.
Acquired more patents and PhD's...now management needs to fund the pharmaceutical division in a way that supports, rather than sacrifices the share price.
Later,
W2P
